Skip to main content

Table 2 Details of ALS-CSF

From: Chitotriosidase - a putative biomarker for sporadic amyotrophic lateral sclerosis

 

CSF for iTRAQ study

CSF for validation

Gender

Male – 7 (70%)

Female – 3 (30%)

Male – 10 (62.5%)

Female – 6 (37.5%)

Age at presentation (Mean ± SD)

47.40 ± 4.95 (38 – 54) Years

47.38 ± 5.38 (38 – 54) Years

Age at onset

46 ± 5.05 (37 – 53) Years

46.28 ± 5.36 (37 – 53) Years

Duration of illness (Mean ± SD)

15.9 ± 13.4 (4.0 – 48) months

14.19 ± 10.59 (4.0 – 48) months

Onset Patter: Bulbar

1 (10%)

5 (31.25%)

Limb onset

9 (90%)

11 (68.75%)

Upper Limbs

9

11

Lower Limbs

6

7

Speech affected

80% (Mild – 30%, Moderate – 30%, Severe – 20%)

87.5% (Mild – 31.25%, Moderate – 31.25%, Severe – 25%)

Dysphagia

80% (Mild – 30%, Moderate – 30%, Severe – 20%)

93.75% (Mild – 31.25%, Moderate – 18.75%, Severe -12.5%)

Spasticity

9 cases, with evidence of pyramidal signs in the form of spasticity and exaggerated Deep Tendon Reflexes

11 cases, with evidence of pyramidal signs in the form of spasticity and exaggerated Deep Tendon Reflexes